Key achievements for fy 2010 / 2011
— A$ 41.3 million raised in successful Capital Raising
— Potency Assay for CVacTM ovarian cancer vaccine successfully
developed
— CVacTM commercialisation plans commenced in the Middle East –
CVacTM at Dubai Healthcare City
— Scientifi c Advice granted provided by EMA regulatory for CVacTM
Phase III Trial
— First patient cohort successfully treated in CVacTM Phase IIb Trial
— New board and management appointments broadens Company skill set
— Orphan Drug Designation granted for CVac™ by US Food and Drug Administration building on EMA
Orphan Product Designation
Martin Rogers
Managing Director & Chief Executive Offi cer (CEO)
Key achievements for fy 2010 / 2011— A$ 41.3 million raised in...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 29.8¢ | 29.0¢ | $539.5K | 1.834M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 214062 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 469318 | 5 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |